Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You

DOI: 10.1007/s11899-016-0336-z
Current Hematologic Malignancy Reports, 2016, 11, 368-84.

#	Paper	IF	Citations
58	Immunotherapy for acute lymphoblastic leukemia: from famine to feast. *Blood Advances*, **2016**, 1, 265-268	7.8	7
57	Next frontiers in CAR T-cell therapy. *Molecular Therapy - Oncolytics*, **2016**, 3, 16028	6.4	17
56	Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies. *Computational and Structural Biotechnology Journal*, **2016**, 14, 357-362	6.8	160
55	Like Angler Fish, CAARs Lure Their Prey. *Molecular Therapy*, **2016**, 24, 1339-41	11.7	6
54	Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy. *Immunological Reviews*, **2017**, 276, 192-212	11.3	36
53	Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants. *Cancer Immunology Research*, **2017**, 5, 571-581	12.5	151
52	Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. *Cancer Discovery*, **2017**, 7, 1154-1167	24.4	98
51	Cell-based immunotherapy with cytokine-induced killer (CIK) cells: From preparation and testing to clinical application. *Human Vaccines and Immunotherapeutics*, **2017**, 13, 1-9	4.4	19
50	Tumor-targeting domains for chimeric antigen receptor T cells. *Immunotherapy*, **2017**, 9, 33-46	3.8	5
49	Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. *BioDrugs*, **2017**, 31, 473-481	7.9	80
48	Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice. *Current Hematologic Malignancy Reports*, **2017**, 12, 370-379	4.4	8
47	Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. *Leukemia*, **2017**, 31, 246-248	10.7	73
46	Immune Checkpoint Blockade in Breast Cancer Therapy. *Advances in Experimental Medicine and Biology*, **2017**, 1026, 383-402	3.6	22
45	CARs on the Highway: Chimeric Antigen Receptor Modified T Cells for the Adoptive Cell Therapy of Malignant Diseases. **2017**,		2
44	Current Perspectives on Emerging CAR-Treg Cell Therapy: Based on Treg Cell Therapy in Clinical Trials and the Recent Approval of CAR-T Cell Therapy. *The Journal of the Korean Society for Transplantation*, **2017**, 31, 157	0.3	
43	Oncolytic viruses as engineering platforms for combination immunotherapy. *Nature Reviews Cancer* , **2018**, 18, 419-432	31.3	194
42	Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety. *Best Practice and Research in Clinical Haematology*, **2018**, 31, 117-125	4.2	2

41	Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering. *Current Opinion in Immunology*, **2018**, 51, 146-153	7.8	128
40	Excessive activated T-cell proliferation after anti-CD19 CAR T-cell therapy. *Gene Therapy*, **2018**, 25, 198-204	4	6
39	CAR T-cell therapy for glioblastoma: ready for the next round of clinical testing?. *Expert Review of Anticancer Therapy*, **2018**, 18, 451-461	3.5	12
38	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. *Medicinal Research Reviews*, **2018**, 38, 325-376	14.4	29
37	Current progress in innovative engineered antibodies. *Protein and Cell*, **2018**, 9, 86-120	7.2	165
36	Immune Modulation Therapy and Imaging: Workshop Report. *Journal of Nuclear Medicine*, **2018**, 59, 410-417	8.1	19
35	Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies. *Leukemia and Lymphoma*, **2018**, 59, 2040-2055	1.9	9
34	The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2018**, 38, 830-837	7.1	13
33	Novel Immunotherapies for T Cell Lymphoma and Leukemia. *Current Hematologic Malignancy Reports*, **2018**, 13, 494-506	4.4	16
32	Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans. *Molecular Therapy*, **2018**, 26, 1401-1403	11.7	11
31	Chimeric Antigen Receptor T-Cells (CAR T-Cells) for Cancer Immunotherapy - Moving Target for Industry?. *Pharmaceutical Research*, **2018**, 35, 152	4.5	57
30	Flow cytometry for minimal residual disease testing in acute leukemia: opportunities and challenges. *Expert Review of Molecular Diagnostics*, **2018**, 18, 775-787	3.8	5
29	A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. *Molecular Therapy*, **2018**, 26, 2487-2495	11.7	42
28	Plasma cell and B cell-targeted treatments for use in advanced multiple sclerosis. *Multiple Sclerosis and Related Disorders*, **2019**, 35, 19-25	4	3
27	Modulation of immune checkpoint molecule expression in mantle cell lymphoma. *Leukemia and Lymphoma*, **2019**, 60, 2498-2507	1.9	10
26	Beat pediatric ALL MRD: CD28 CAR T and transplant. *Blood*, **2019**, 134, 2333-2335	2.2	3
25	From Biology to Therapy: The CLL Success Story. *HemaSphere*, **2019**, 3, e175	0.3	29
24	Naïve T-cell Deficits at Diagnosis and after Chemotherapy Impair Cell Therapy Potential in Pediatric Cancers. *Cancer Discovery*, **2019**, 9, 492-499	24.4	90

23	Emerging Cellular Therapies for Cancer. *Annual Review of Immunology*, **2019**, 37, 145-171	34.7	175
22	The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape. *Nature Biotechnology* , **2020**, 38, 1387-1394	44.5	4
21	B-Cell Maturation Antigen (BCMA) as a Target for New Drug Development in Relapsed and/or Refractory Multiple Myeloma. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	13
20	Manufacturing and Management of CAR T-Cell Therapy in "COVID-19 Time": Central Versus Point of Care Proposals. *Frontiers in Immunology*, **2020**, 11, 573179	8.4	7
19	A narrative review of critical factors for better efficacy of CD19 chimeric antigen receptor T cell therapy in the treatment of B cell malignancies.. *Translational Cancer Research*, **2020**, 9, 5655-5662	0.3	
18	CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview. *Bone Marrow Transplantation*, **2020**, 55, 1525-1532	4.4	11
17	CAR-T TREK through the lymphoma universe, to boldly go where no other therapy has gone before. *British Journal of Haematology*, **2021**, 193, 449-465	4.5	3
16	Novel CD37, Humanized CD37 and Bi-Specific Humanized CD37-CD19 CAR-T Cells Specifically Target Lymphoma. *Cancers*, **2021**, 13,	6.6	5
15	Global Perspective on the Development of Genetically Modified Immune Cells for Cancer Therapy. *Frontiers in Immunology*, **2020**, 11, 608485	8.4	2
14	Chimeric antigen receptor-engineered natural killer cells: a promising cancer immunotherapy. *Expert Review of Clinical Immunology*, **2021**, 17, 643-659	5.1	2
13	Cellular Therapy with Engineered T Cells, Efficacy and Side Effects. **2019**, 449-456		2
12	Adoptive cell therapy: Living drugs against cancer. *Journal of Experimental Medicine*, **2020**, 217,	16.6	7
11	T cells expressing chimeric antigen receptor promote immune tolerance. *JCI Insight*, **2017**, 2,	9.9	42
10	Lingering effects of chemotherapy on mature T cells impair proliferation. *Blood Advances*, **2020**, 4, 4653-4664	7.6	7
9	CAR-T Cell Clinical Trials Experience Past, Present and Future. **2020**, 303-375		
8	Membrane-proximal external region is a superior target for mediating effector activity of HIV-1 specific chimeric antigen receptor modified T cells.		
7	Emerging immunotherapeutics in adenocarcinomas: A focus on CAR-T cells. *Current Trends in Immunology*, **2016**, 17, 95-115	4	12
6	Editorial: T-Cell Signaling Networks in Health and Disease.. *Frontiers in Immunology*, **2022**, 13, 875580	8.4	

5	CAR-T Engager Proteins Optimize Anti-CD19 CAR-T Cell Therapies for Lymphoma.	
4	Transition from serum-supplemented monolayer to serum-free suspension lentiviral vector production for generation of chimeric antigen receptor T cells. *Cytotherapy*, **2022**,	4.8
3	Cancer immunotherapy: diverse approaches and obstacles. **2022**, 28,	0
2	CAR-T Engager proteins optimize anti-CD19 CAR-T cell therapies for lymphoma. **2022**, 11,	0
1	Anti-ROR1 CAR-T cells: Architecture and performance. 10,	0